News
LPTX
1.010
-15.83%
-0.190
Leap Therapeutics To Present Initial Data From The Investigator-sponsored Study Of Dkn-01 Plus Docetaxel In Patients With Prostate Cancer At The 2022 ASCO Annual Meeting June 3-7
Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting CAMBRIDGE, Mass., May 26,
Benzinga · 16h ago
Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that initial clinical data from the investigator-sponsored Phase 1b/2a dose escalation and dose expansion study...
PR Newswire · 16h ago
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe
Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The recent label expansion nod to Oxbryta is a positive. However, sole dependence on Oxbryta for growth is a concern.
Zacks · 22h ago
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.
Zacks · 1d ago
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
Zacks · 1d ago
Seagen (SGEN) Posts Positive Data from New Study on Tukysa
Seagen (SGEN) reports favorable data on the pivotal phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin for treating HER2-positive metastatic colorectal cancer.
Zacks · 2d ago
AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate
AbbVie (ABBV) submits a new drug application to the FDA for ABBV-951, which has been developed for treating advanced Parkinson's disease.
Zacks · 3d ago
Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata
The CHMP gives a positive opinion and recommends approval of Lilly's (LLY) Olumiant to treat adults with severe alopecia areata.
Zacks · 3d ago
We're Keeping An Eye On Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 05/19 10:15
Harpoon Therapeutics, Grove top healthcare gainers; Chimerix, Eliem lead losers' pack
Gainers: Harpoon Therapeutics (HARP) +18%. Grove (GRVI) +11%. NanoViricides (NNVC) +11%. Travere Therapeutics (TVTX) +9%. Compass Therapeutics (CMPX) +4%. Losers: Chimerix (CMRX) -58%. Eliem Therapeutics (ELYM) -29%. Humacyte (HUMA) -20%. Valneva (VALN) -2...
Seekingalpha · 05/16 14:03
110 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
Benzinga · 05/16 09:23
Leap Therapeutics GAAP EPS of -$0.09 beats by $0.01
Leap Therapeutics press release (NASDAQ:LPTX): Q1 GAAP EPS of -$0.09 beats by $0.01. Cash and cash equivalents totaled $103.2 million at March 31, 2022. Shares +2.73% PM.
Seekingalpha · 05/13 11:47
Shareholders in Leap Therapeutics (NASDAQ:LPTX) are in the red if they invested five years ago
Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic...
Simply Wall St. · 04/09 12:57
Leap Therapeutics's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q4, Leap Therapeutics's (NASDAQ:LPTX) reported sales totaled $375.00 thousand. Despite a 3.15% increase in earnings, the company posted a loss of $10.79 million.
Benzinga · 03/15 15:07
The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 03/11 12:52
Leap Therapeutics: Q4 Earnings Insights
  Leap Therapeutics (NASDAQ:LPTX) reported its Q4 earnings results on Friday, March 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 03/11 12:50
Leap Therapeutics GAAP EPS of -$0.10 beats by $0.01, revenue of $0.38M beats by $0.08M
Leap Therapeutics press release (NASDAQ:LPTX): Q4 GAAP EPS of -$0.10 beats by $0.01. Revenue of $0.38M (flat Y/Y) beats by $0.08M. CEO comment: "Following our public offering, we are well
Seekingalpha · 03/11 12:33
BRIEF-Leap Therapeutics Reports Qtrly Loss Per Share Of $0.10
reuters.com · 03/11 12:07
Leap Therapeutics Q4 EPS $(0.10) Down From $(0.09) YoY, Sales $375.00K, Same YoY
Leap Therapeutics (NASDAQ:LPTX) reported quarterly losses of $(0.10) per share. This is a 11.11 percent decrease over losses of $(0.09) per share from the same period last year. The company reported $375.00 thousand in
Benzinga · 03/11 12:04
Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer will present a corporate overview at Raymond James ...
PR Newswire · 03/02 12:00
More
Webull provides a variety of real-time LPTX stock news. You can receive the latest news about Leap Therapeutic through multiple platforms. This information may help you make smarter investment decisions.
About LPTX
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company has two product pipelines: DKN-01 and TRX518. The Company's lead clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models. TRX518 is a humanized anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody designed for the immune system’s anti-tumor response as an immune checkpoint agonist.